Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT06169345 Completed - Heart Failure Clinical Trials

The Long-term Course of Moderate Tricuspid Regurgitation

LOCOMOTRI
Start date: May 1, 2021
Phase:
Study type: Observational

To evaluate the long-term clinical outcome of a cohort of patients suffering from moderate tricuspid regurgitation (TR), regardless of its etiology.

NCT ID: NCT06099028 Completed - Heart Failure Clinical Trials

Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China

Start date: September 1, 2021
Phase:
Study type: Observational

This is a retrospective, researcher-initiated, database-based study that will retrospectively observe the treatment and medication patterns of about 22,500 patients with heart failure from 25 heart failure centers and 25 non-heart failure centers in the database of heart failure center. The proportion of patients with heart failure treatment drugs reaching the target dose recommended in the guidelines and discontinuation rate will be observed at 1 month, 3 months and 12 months follow up time point. The purpose of this study is to illustrate the current HF treatment status in HF center hospitals and non-HF center hospitals, which may provide insights for improving the clinical practice of heart failure treatment in China, and promote the standardization of heart failure treatment in China.

NCT ID: NCT06092658 Completed - Clinical trials for Analyze Etiology, Comorbidities, Clinical Characteristics

Cohort Study of Chronic Heart Failure

Start date: November 20, 2012
Phase:
Study type: Observational

The purpose is to understand the clinical characteristics of chronic heart failure as soon as possible, analyze the etiology, comorbidities, clinical characteristics, and treatment of heart failure patients, observe the gap between real-world clinical practice and guideline recommendations, and provide reference for the improvement of heart failure prevention and treatment in China.

NCT ID: NCT06070506 Completed - Heart Failure Clinical Trials

Heart Failure With Improved Ejection Fraction and Deep Learning

Start date: March 1, 2022
Phase:
Study type: Observational

The aim of this study was to design a deep learning-based trained model to assist in HFimpEF diagnosis.

NCT ID: NCT06068725 Completed - Heart Failure Clinical Trials

The Effect of Video Training o Symptom Management With Heart Failure

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to compare the effect of video-assisted training on the quality of life and symptom management of patients over the age of 65. The main questions it aims to answer are: -Is there a difference between symptom management and quality of life between the first and last follow-up periods of patients in the application and control groups?

NCT ID: NCT06068166 Completed - Clinical trials for Heart Failure With Reduced Ejection Fraction

Thoracic Epidural Anesthesia Reduces Mortality and Rehospitalization for Patients With Heart Failure With Reduced Ejection Fraction

Start date: July 1, 2013
Phase: N/A
Study type: Interventional

Despite significant scientific breakthrough in management, patients with heart failure with reduced ejection fraction (HFrEF) remain high morbidity and mortality, with a 5-year survival rate of 25% after hospitalization for HFrEF. The autonomic nervous system (ANS), particularly the sympathetic nervous system (SNS), plays a critical compensatory role in maintaining cardiovascular homeostasis in the failing heart. This is critical given the huge unmet need for novel treatment strategies for HFrEF. Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures. Since 1995, Professor Liu Fengqi has pioneered the use of TEA to treat end-stage HFrEF and achieved surprising results. TEA could reduce the enlarged heart cavity, halt and reverse cardiac remodeling, and improve cardiac systolic and diastolic function. Currently, thousands of HFrEF patients have received TEA procedure. However, it is unclear whether TEA could positively impact the clinical outcomes of patients with HFrEF.

NCT ID: NCT06065566 Completed - Clinical trials for Insufficiency;Cardiac

Effect of Parenteral Glutamine on Myocardial Injury and Inflammation Biomarkers

Start date: February 4, 2020
Phase: N/A
Study type: Interventional

The effect of parenteral glutamine on the biomarkers of myocardial injury and inflammation in patients undergoing cardiac surgery with and without cardiopulmonary bypass (DCP) will be analyzed. Randomized controlled clinical trial, from October 2018 to February 2022. 124 patients: 14 patients with DCP and 14 patients without DCP, both + glutamine (L-alanyl-L-glutamine dipeptide, at a dose of 0.4 g / kg) 6 hours before surgery and 14 patients with PCD and 14 patients without PCD + placebo (saline) 6 hours before surgery. Blood samples will be taken to measure the level of TROP-I, CPK-MB, HSP-70, TNFa, IL6, IL10 and PCR 1 hour before the administration of Glutamine / Placebo, 1 hour before surgery, then at 1 , 12 and 24 hours after surgery.

NCT ID: NCT06060223 Completed - Heart Failure Clinical Trials

Teach Back Method in Individuals With Heart Failure

Start date: October 3, 2022
Phase: N/A
Study type: Interventional

This study will be conducted to determine the effect of the training given to indivuduals with heart failure by teach back method on their symptom control, adherence to treatment and self care behaviours.

NCT ID: NCT06039397 Completed - Heart Failure Clinical Trials

The Effect of Semi Fowler 30' Right Lateral on Cardiac Output in Acute Heart Failure

SETTLECO
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Heart failure is a special clinical syndrome such as difficulty breathing, fatigue, and swollen legs characterized by increased JVP, crackle lung sounds, and peripheral edema caused by heart disorders both structural and/or functional, resulting in decreased cardiac output and increased intracardiac pressure at rest and activity. Body positioning has been shown to affect stroke volume and parasympathetic modulating activity. The right lateral 30" semifowler position is a very safe position in heart failure patients admitted to the ICU. Although body positioning can affect stroke volume, and parasympathetic modulation, it is not yet clear what effect it has on cardiac output

NCT ID: NCT06029452 Completed - ATTR-CM Clinical Trials

A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).

Start date: September 1, 2023
Phase:
Study type: Observational

This is an observational, retrospective non-inferiority study with a study sample from a large national database. A machine learning (ML) model will use a national database to predict the clinical diagnosis of ATTRwt-CM among HF patients. This study will include HF patients ≥50 years old.